PRQR - ProQR Therapeutics N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.47
-0.21 (-1.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.68
Open11.78
Bid0.00 x 800
Ask0.00 x 900
Day's Range11.38 - 11.90
52 Week Range3.50 - 24.00
Volume174,025
Avg. Volume236,346
Market Cap445.872M
Beta (3Y Monthly)0.11
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateMay 7, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    ProQR to Present at Three Scientific Conferences in April

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswire7 days ago

    ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

    LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • GlobeNewswire7 days ago

    ProQR Announces Annual Meeting of Shareholders

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • ProQR Initiates Dosing in Phase II/III Eye Disorder Study
    Zacks8 days ago

    ProQR Initiates Dosing in Phase II/III Eye Disorder Study

    ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

  • GlobeNewswire10 days ago

    ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 2/3 ILLUMINATE clinical trial for sepofarsen (formerly named QR-110) in patients with Leber’s Congenital Amaurosis 10 (LCA10). “Inherited retinal degenerations caused by mutations in the CEP290 gene frequently lead to blindness in early childhood. No form of therapy is currently available,” said Dr. Katarina Stingl of the Center for Ophthalmology in Tübingen, Investigator in the ILLUMINATE trial.

  • GlobeNewswire24 days ago

    ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswirelast month

    ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out of the Dystrophic Epidermolysis Bullosa (DEB) activities into the newly formed company, Wings Therapeutics. Wings Therapeutics is formed and financed by EB Research Partnership (EBRP), the largest global non-profit dedicated to treating and curing EB. Wings Therapeutics will be led by interim CEO Mark de Souza, PhD, former CEO of Lotus Tissue Repair and Hal Landy, MD, former medical advisor to Lotus Tissue Repair and CMO of Enobia.

  • GlobeNewswirelast month

    ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). "There are no effective treatments for most inherited retinal diseases, including Usher syndrome, and blindness often results,” said David G. Birch, Ph.D., Principal Investigator of STELLAR and Scientific Director of the Retina Foundation of the Southwest in Dallas, Texas. “The STELLAR study is one of the first studies of its kind exploring the impact of ProQR’s RNA therapies on patients with Usher syndrome due to an Exon 13 mutation.

  • GlobeNewswire2 months ago

    ProQR to Present at Cowen Health Care Conference

    LEIDEN, Netherlands and CAMBRIDGE, Mass., March 05, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
    Zacks2 months ago

    Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus

    The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.

  • GlobeNewswire2 months ago

    ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

    LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
    Zacks2 months ago

    Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer

    Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.

  • Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
    Zacks3 months ago

    Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids

    Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.

  • GlobeNewswire3 months ago

    ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and commercialization of RNA medicines for inherited retinal diseases (IRDs). The management team will elaborate on this strategy and present advancements across its broader clinical development pipeline during an R&D day event being held today in New York. ProQR plans to independently advance its pipeline of RNA medicines to establish a multi-product, platform company in IRD.

  • Should You Worry About ProQR Therapeutics N.V.’s (NASDAQ:PRQR) CEO Salary Level?
    Simply Wall St.3 months ago

    Should You Worry About ProQR Therapeutics N.V.’s (NASDAQ:PRQR) CEO Salary Level?

    Daniel de Boer became the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) in 2012. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...

  • GlobeNewswire4 months ago

    ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached agreement with  the U.S. Food and Drug Administration (FDA) on the design of a Phase 2/3 pivotal trial (“ILLUMINATE”) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. LCA is the leading genetic cause of childhood blindness. Based on data from the ongoing sepofarsen Phase 1/2 trial (PQ-110-001), the doses for the Phase 2/3 trial will be 40 μg (with an 80 μg loading dose) and 80 μg (with a 160 μg loading dose).

  • Company News For Jan 3, 2019
    Zacks4 months ago

    Company News For Jan 3, 2019

    Companies in the news are: GOOGL, TSLA, PRQR, OHI and MRT

  • GlobeNewswire4 months ago

    ProQR to Host R&D Day in New York on January 29

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks4 months ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • GlobeNewswire4 months ago

    ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. Fast Track designation is granted by FDA to drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need.

  • GlobeNewswire4 months ago

    ProQR Therapeutics Added to NASDAQ Biotechnology Index

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 24, 2018 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds?
    Insider Monkey4 months ago

    Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds?

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost a third of its value since the end of July. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 30 S&P 500 stocks […]

  • GlobeNewswire4 months ago

    ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Nature Medicine. “It was enormously gratifying to see robust improvements in visual acuity and significant augmentations in the patient’s ability to detect lights, and impressive to observe these effects within the first three months following a single injection,” said Professor Artur V. Cideciyan, Ph.D., who was one of the co-investigators at the Scheie Eye Institute of the University of Pennsylvania.

  • GlobeNewswire4 months ago

    ProQR Announces Strategic Changes to the Management Team and Key New Hires

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation.

  • GlobeNewswire4 months ago

    ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it was awarded an innovation credit by the Dutch government for the clinical development and efforts to obtain marketing approval (NDA/MAA) for the QR-110 program that is being developed for patients with Leber’s congenital amaurosis 10 (LCA10), a genetic eye disease that is the leading cause of childhood blindness. Repayment of the credit is triggered only by market approval of QR-110. The Innovation Credit is awarded by the Dutch government through its agency RVO of the Ministry of Economic Affairs, and is aimed at the development of promising innovations.